Human gastric cancer peritoneal metastasis ascites-derived cell line and application thereof

Abstract

This invention belongs to the field of biomedical technology, specifically relating to a human-derived cell line for peritoneal metastasis of gastric cancer and its applications. The invention involves collecting ascites from gastric cancer patients and culturing it into organoids. These organoids are then transplanted subcutaneously into immunodeficient mice to form xenografts (PDOX). The transplanted organoids are digested and passaged in vitro to obtain a purified cell line. The primary isolated cell line is then inoculated into the peritoneal cavity of immunodeficient mice to induce the formation of metastatic ascites. Cells are extracted from the metastatic ascites and cultured again into organoids to construct human gastric cancer ascites cells, named BZGC. The cell line constructed in this invention has the ability to form 100% metastatic ascites in the mouse peritoneal cavity, fully simulating the entire process of ascites formation in gastric cancer peritoneal metastasis. The human-derived gastric cancer ascites cells described in this invention provide a stable, reliable, and highly clinically and pathologically similar in vitro and in vivo model for studying the mechanism of gastric cancer peritoneal metastasis, drug screening, and personalized treatment.

Images